Lista de obras -

A Human Cell Line Model for Interferon-α Driven Dendritic Cell Differentiation

artículo científico publicado en 2015

A New Flowcytometry-Based Method to Discriminate Malignant From Normal Stem Cells in CML. ⬇️

artículo científico publicado en 2009

A phase I first-in-human study with tefinostat - a monocyte/macrophage targeted histone deacetylase inhibitor - in patients with advanced haematological malignancies

artículo científico publicado en 2013

ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects--a review

artículo científico publicado en 2003

Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes ⬇️

artículo científico publicado el 5 de septiembre de 2010

Antibody-targeted therapy: a paradigm of innovative treatment strategies in indolent and aggressive B-cell non-Hodgkin lymphoma

artículo científico publicado en 2004

Apoptosis resistance and response to chemotherapy in primary nodal diffuse large B-cell lymphoma

artículo científico publicado en 2006

Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry

artículo científico publicado en 2008

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia

artículo científico publicado en 2014

C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia

artículo científico publicado en 2004

CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age.

artículo científico publicado en 2007

Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses

artículo científico publicado en 2009

Cytarabine dose for acute myeloid leukemia

artículo científico publicado en 2011

Dendritic cell-based immunotherapy in acute and chronic myeloid leukaemia

artículo científico publicado en 2007

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

artículo científico publicado en 2016

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

artículo científico publicado en 2009

Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors

artículo científico publicado en 2014

Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia

artículo científico publicado en 2009

Emerging antibody-targeted therapy in leukemia and lymphoma: current concepts and clinical implications

artículo científico publicado en 2004

Employing the immunological synapse in AML: development of leukemic dendritic cells for active specific immunization

artículo científico publicado en 2005

Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma

artículo científico publicado en 2002

Expression of the polycomb-group gene BMI1 is related to an unfavourable prognosis in primary nodal DLBCL.

artículo científico publicado en 2006

Feasibility of clinical dendritic cell vaccination in acute myeloid leukemia

artículo científico publicado en 2006

Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial

artículo científico publicado en 2017

High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients

artículo científico publicado en 2003

High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study

artículo científico publicado en 2013

High-dose daunorubicin in older patients with acute myeloid leukemia

artículo científico publicado en 2009

Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome

artículo científico publicado en 2009

Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis

artículo científico publicado en 2017

Leukaemia cutis: clinical features and treatment strategies

artículo científico publicado en 2002

Leukemia-derived dendritic cells: towards clinical vaccination protocols in acute myeloid leukemia.

artículo científico publicado en 2006

Molecular targeted therapies for diffuse large B-cell lymphoma based on apoptosis profiles.

scientific article published on April 2010

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

artículo científico publicado en 2007

Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells

artículo científico publicado en 2013

Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia

artículo científico publicado en 2011

Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia

artículo científico publicado en 2010

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

artículo científico publicado en 2011

Principles of dendritic cell-based immunotherapy in myeloid leukemia

artículo científico publicado en 2006

Promiscuous binding of invariant chain-derived CLIP peptide to distinct HLA-I molecules revealed in leukemic cells

artículo científico publicado en 2012

Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia

artículo científico publicado en 2016

Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome

artículo científico publicado en 2010

Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily

artículo científico

Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients

artículo científico publicado en 2013

Small-molecule XIAP antagonist restores caspase-9 mediated apoptosis in XIAP-positive diffuse large B-cell lymphoma cells

artículo científico publicado en 2007

The European LeukemiaNet: achievements and perspectives

artículo científico publicado en 2010

The Prognostic Value of CD34 Expression In Acute Myeloid Leukemia. A Mystery Solved ⬇️

artículo científico publicado en 2010

The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells

artículo científico publicado en 2007

Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia

artículo científico publicado en 2014

Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial

artículo científico publicado en 2010

Value of infliximab (Remicade(R)) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group ⬇️

artículo científico publicado el 18 de noviembre de 2011

Lista de obras de

A Human Cell Line Model for Interferon-α Driven Dendritic Cell Differentiation

A New Flowcytometry-Based Method to Discriminate Malignant From Normal Stem Cells in CML. ⬇️

A phase I first-in-human study with tefinostat - a monocyte/macrophage targeted histone deacetylase inhibitor - in patients with advanced haematological malignancies

ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects--a review

Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes ⬇️

Antibody-targeted therapy: a paradigm of innovative treatment strategies in indolent and aggressive B-cell non-Hodgkin lymphoma

Apoptosis resistance and response to chemotherapy in primary nodal diffuse large B-cell lymphoma

Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia

C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia

CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age.

Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses

Cytarabine dose for acute myeloid leukemia

Dendritic cell-based immunotherapy in acute and chronic myeloid leukaemia

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors

Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia

Emerging antibody-targeted therapy in leukemia and lymphoma: current concepts and clinical implications

Employing the immunological synapse in AML: development of leukemic dendritic cells for active specific immunization

Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma

Expression of the polycomb-group gene BMI1 is related to an unfavourable prognosis in primary nodal DLBCL.

Feasibility of clinical dendritic cell vaccination in acute myeloid leukemia

Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial

High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients

High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study

High-dose daunorubicin in older patients with acute myeloid leukemia

Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome

Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis

Leukaemia cutis: clinical features and treatment strategies

Leukemia-derived dendritic cells: towards clinical vaccination protocols in acute myeloid leukemia.

Molecular targeted therapies for diffuse large B-cell lymphoma based on apoptosis profiles.

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells

Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia

Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

Principles of dendritic cell-based immunotherapy in myeloid leukemia

Promiscuous binding of invariant chain-derived CLIP peptide to distinct HLA-I molecules revealed in leukemic cells

Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia

Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome

Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily

Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients

Small-molecule XIAP antagonist restores caspase-9 mediated apoptosis in XIAP-positive diffuse large B-cell lymphoma cells

The European LeukemiaNet: achievements and perspectives

The Prognostic Value of CD34 Expression In Acute Myeloid Leukemia. A Mystery Solved ⬇️

The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells

Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia

Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial

Value of infliximab (Remicade(R)) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group ⬇️